What are the current recommendations for suppressive therapy in women with recurrent vulvovaginal candidiasis (≥4 episodes in the past year)?

Suppressive Therapy for Recurrent Vulvovaginal Candidiasis

For women with recurrent vulvovaginal candidiasis (≥3 episodes per year), initiate maintenance therapy with oral fluconazole 150 mg weekly for 6 months after achieving clinical remission with an induction regimen. 1

Treatment Algorithm

Step 1: Induction Phase

• Administer fluconazole 150 mg orally every 72 hours for three doses to achieve clinical remission 2
• Confirm diagnosis with positive culture/microscopy before starting maintenance therapy

Step 2: Maintenance Phase

• Standard regimen: Fluconazole 150 mg orally once weekly for 6 months 1, 2
• This achieves disease-free status in approximately 91% of women at 6 months 2
• Alternative oral option: Itraconazole weekly (though fluconazole is preferred) 3
• Alternative topical option: Clotrimazole weekly (equally effective during active treatment but less effective long-term) 3

Step 3: Post-Treatment Expectations

• After discontinuing 6-month maintenance therapy, expect median time to recurrence of 10.2 months (compared to 4.0 months with placebo) 2
• Approximately 43% of women remain disease-free at 12 months 2
• Critical caveat: More than 63% of women experience ongoing infections after completing maintenance therapy, so recurrence is common rather than exceptional 1

Emerging Superior Option

Oteseconazole represents a paradigm shift in suppressive therapy and should be considered when available. 1, 3 This novel oral antifungal demonstrates:

• 96% reduction in recurrence at 48 weeks (4% vs 52% with placebo) 1
• Superior efficacy to all other regimens in preventing both clinical and mycological recurrence after therapy discontinuation 3
• More than 90% reduction in late recurrence rates compared to fluconazole/itraconazole 3

Important Clinical Considerations

Quality of Life Impact

Maintenance fluconazole improves quality of life in 96% of women 1, addressing not just physical symptoms but also the substantial psychological burden including low self-esteem, sexual dysfunction, and work productivity loss (estimated $4.7 billion annually in the US) 1

Species-Specific Concerns

• Consider non-albicans species (particularly C. glabrata) in treatment failures 1
• Antifungal susceptibility testing at vaginal pH 4 (not standard laboratory pH 7) reveals clinically relevant resistance, particularly with terconazole against C. glabrata (388-fold higher MIC at pH 4) 1
• This pH-dependent resistance may explain many treatment failures

Resistance Patterns

The evidence shows no emergence of fluconazole resistance in C. albicans isolates during long-term weekly therapy, and no superinfection with C. glabrata during standard maintenance regimens 2. However, geographic variation exists, with some regions reporting concerning resistance rates 4.

Treatment Duration

While 6 months is the standard evidence-based duration 2, women with documented multiple recurrences may benefit from longer courses 5. The trade-off is that longer suppression delays but does not prevent eventual recurrence in most cases.

Practical Implementation

• Do not wait for 4 episodes (outdated definition); current standard is ≥3 episodes per year 1
• Do not use alternative therapies (probiotics, honey-based products, essential oils) as primary maintenance—they are inferior to FDA-approved azoles 1
• Do not routinely treat partners—this does not enhance cure rates for candidiasis (unlike trichomoniasis) 5
• Do not perform test of cure after successful induction unless symptoms persist

Monitoring

• Assess clinical response at 6 months
• Counsel patients that recurrence after stopping maintenance is common, not treatment failure
• Consider restarting maintenance therapy if recurrence occurs after initial course

The evidence strongly supports maintenance fluconazole as first-line suppressive therapy, with oteseconazole emerging as a superior but newer alternative when accessible. 1, 3, 2